Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

Rosell, Rafael; Gatzemeier, U.; Betticher, Daniel; Keppler, U.; Macha, H.-N.; Pirker, Robert; Berthet, Pascaline; Breau, J. L.; Lianes, P.; Nicholson, M.; Ardizzoni, Andrea; Chemaissani, A.; Bogaerts, Jan; Gallant, G.

doi:10.1093/annonc/mdf332

Cited by 273 publications

(186 citation statements)

References 25 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, treatment with cisplatin and gemcitabine was associated with more renal toxicity (Schiller et al, 2002). Recently, Rosell et al (2002) compared two platinum-based regimens and showed that a cisplatin-based therapy was associated with a significantly longer median survival. However, in our trial, response rates and survival were similar in both arms, but the nonplatinum-containing regimen had a less favourable toxicity profile.…”

Section: Discussionmentioning

confidence: 99%

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial

Wachters¹,

Putten²,

Kramer³

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

The purpose of our study was to compare progression-free survival and quality of life (QOL) after cisplatin -gemcitabine (CG) or epirubicin -gemcitabine (EG) in chemotherapy-naive patients with unresectable non-small-cell lung cancer. Patients (n ¼ 240) were randomised to receive gemcitabine 1125 mg m À2 (days 1 and 8) plus either cisplatin 80 mg m À2 (day 2) or epirubicin 100 mg m À2 (day 1) every 3 weeks for a maximum of five cycles. Eligible patients had normal organ functions and Eastern Cooperative Oncology Group performance status p2. QOL was measured with European Organisation for Research and Treatment of Cancer QLQ-C30 and LC13 questionnaires. There were no significant differences in median progression-free survival (CG 26 weeks, EG 23 weeks), median overall survival (CG 43 weeks, EG 36 weeks), or tumour response rates (CG 46%, EG 36%). Toxicity was mainly haematologic. In the EG arm granulocytopenia occurred more frequently, leading to more febrile neutropenia. Also, elevation of serum transaminases, mucositis, fever, and decline in LVEF were more common in the EG arm. In the CG arm, more patients experienced elevated serum creatinine levels, sensory neuropathy, nausea, and vomiting. Global QOL was not different in both arms. Progression-free survival, overall survival, response rate, and QOL were not different between both arms; however, overall toxicity was more severe in the EG arm.

show abstract

Section: Discussionmentioning

confidence: 99%

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial

Wachters¹,

Putten²,

Kramer³

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Several trials in the past compared regimens containing cisplatin vs carboplatin with conflicting results [26][27][28][29][30][31][32][33]. In 2007, an individual patient data meta-analysis performed by Ardizzoni et al [34], including 9 of these trials and comparing cisplatin VS carboplatin-based chemotherapy in 2968 NSCLC patients, showed a significant improvement of ORR in favour of cisplatin arm (30% VS 24%; OR: 1.37, P < 0.001), while no significant differences between two arms were observed in survival rate.…”

Section: Citaɵonmentioning

confidence: 99%

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Bronte

Rolfo

Passiglia

et al. 2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…Meanwhile, paclitaxel carboplatin chemotherapy would also cause thrombocytopenia in 58% of ovarium cancer patients [26]. Research by Rosell et al also showed that paclitaxel carboplatin regimen would cause a higher risk of thrombocytopenia for as much as 27% compared to 13% in non-small-cell-lung cancer patients with paclitaxel cisplatin regimen [27]. This result is in accordance to another research by Bois et al that stated how combined paclitaxel and cisplatin chemotherapies will cause toxicity in thrombocyte, erythrocyte, leukocyte, neutrophil, and neutropenia [28].…”

Section: Difference In Blood Function Toxicitymentioning

confidence: 99%

Difference in Blood Function Toxicity Between Stadium Iib-Iiib Squamous Cell Cervical Cancer Patients With Paclitaxel Cisplatin and Paclitaxel Carboplatin Chemotherapy at Sanglah Hospital, Denpasar.

Indrayathi

Noviyani

Niruri

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Paclitaxel cisplatin and paclitaxel carboplatin were chemotherapy regimens used for cervical cancer treatments at Sanglah Hospital, Denpasar. They came with hematologic toxicity side effects. This could be monitored from hemoglobin, thrombocyte, and leukocyte parameter. Data that compared the toxicity of these two regimens were still limited at Sanglah Hospital, Denpasar. Therefore, it was necessary to conduct a research about the difference in blood function toxicity between patients who underwent paclitaxel cisplatin chemotherapy and those who underwent paclitaxel carboplatin chemotherapy based on those three parameters.Methods: This was a prospective observational research with consecutive sampling, inclusion, and exclusion criteria. It was carried out from January to August 2016 at Sanglah Hospital, Denpasar. Patients were categorized into two groups based on their chemotherapy regimens. Next, blood samples from both groups were tested for its hemoglobin, thrombocyte, and leukocyte level before and after chemotherapy. The data underwent normality test using either Shapiro-Wilk or Mann-Whitney test with SPSS.Results: There were 17 patients who fulfilled the inclusion criteria. The result showed a decrease in hemoglobin, thrombocyte, as well as leukocyte values in patients who underwent paclitaxel cisplatin and paclitaxel carboplatin chemotherapy. Conclusion:The decrease of both hemoglobin and leukocyte level was not meaningful in both groups (p>0.05). Meanwhile, the decrease of thrombocyte level was meaningful in both groups (*p<0.05) in which patients who belong to paclitaxel carboplatin chemotherapy group showed a higher decrease of thrombocyte values.

show abstract

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

Cited by 273 publications

References 25 publications

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Difference in Blood Function Toxicity Between Stadium Iib-Iiib Squamous Cell Cervical Cancer Patients With Paclitaxel Cisplatin and Paclitaxel Carboplatin Chemotherapy at Sanglah Hospital, Denpasar.

Contact Info

Product

Resources

About